Barclays Maintains an 'Overweight' on Teva Pharma (TEVA); Takeaways from HC Conference Events
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Price: $13.01 --0%
Rating Summary:
12 Buy, 25 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Rating Summary:
12 Buy, 25 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
Barclays maintains an 'Overweight' on Teva Pharma (NASDAQ: TEVA), PT $70.
Barclays analyst says, "With currently-marketed MS drug Copaxone and late development stage drug oral laquinimod key focus items for investors, Jon provided important insights on Teva's MS franchise, as well as strategy and outlook - not only at our lunch meeting, but also as part of Teva's presentation at the conference, which was entirely focused on Teva Neuroscience's products and activities. Among the key items of investor interest: (1) upcoming laquinimod first-time detailed Phase 3 trial results (ALEGRO) at AAN meeting (Apirl 9-16), with the presentation scheduled for April 15 at 6:00pm ET (date/time having been released by the AAN earlier this week); (2) second Phase 3 results in early 3Q (BRAVO); and (3) how laquinimod will be positioned with Copaxone in the market, assuming the former gains regulatory approval within the next 18 months."
"For share price performance, we view key drivers as quarterly financial results and resolution of manufacturing compliance issues, followed by improving earnings visibility as 2012 approaches."
For more ratings news on Teva Pharma click here and for the rating history of Teva Pharma click here.
Shares of Teva Pharma closed at $47.95 yesterday.
Barclays analyst says, "With currently-marketed MS drug Copaxone and late development stage drug oral laquinimod key focus items for investors, Jon provided important insights on Teva's MS franchise, as well as strategy and outlook - not only at our lunch meeting, but also as part of Teva's presentation at the conference, which was entirely focused on Teva Neuroscience's products and activities. Among the key items of investor interest: (1) upcoming laquinimod first-time detailed Phase 3 trial results (ALEGRO) at AAN meeting (Apirl 9-16), with the presentation scheduled for April 15 at 6:00pm ET (date/time having been released by the AAN earlier this week); (2) second Phase 3 results in early 3Q (BRAVO); and (3) how laquinimod will be positioned with Copaxone in the market, assuming the former gains regulatory approval within the next 18 months."
"For share price performance, we view key drivers as quarterly financial results and resolution of manufacturing compliance issues, followed by improving earnings visibility as 2012 approaches."
For more ratings news on Teva Pharma click here and for the rating history of Teva Pharma click here.
Shares of Teva Pharma closed at $47.95 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs on Meta Platforms Inc. (META): 'We expect investors to have an initial negative reaction'
- Teradyne (TER) Tops Q1 EPS by 18c
- First Bancorp. (FBNC) Misses Q1 EPS by 2c
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Barclays, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
